Short Interest in Bavarian Nordic (OTCMKTS:BVNRY) Drops By 41.9%

Bavarian Nordic (OTCMKTS:BVNRY) was the target of a large decline in short interest during the month of December. As of December 15th, there was short interest totaling 1,921 shares, a decline of 41.9% from the November 30th total of 3,307 shares. Based on an average daily trading volume, of 5,050 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.0% of the shares of the company are short sold. Currently, 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 5,050 shares, the days-to-cover ratio is currently 0.4 days.

Bavarian Nordic Stock Up 2.4%

Shares of OTCMKTS BVNRY opened at $10.00 on Monday. The firm’s 50-day moving average price is $10.36 and its 200-day moving average price is $10.89. Bavarian Nordic has a 52-week low of $6.60 and a 52-week high of $13.00. The company has a market cap of $2.38 billion, a PE ratio of 6.45 and a beta of 1.37.

Bavarian Nordic (OTCMKTS:BVNRY) last issued its quarterly earnings data on Friday, November 14th. The company reported $0.72 earnings per share for the quarter. Bavarian Nordic had a net margin of 35.96% and a return on equity of 20.47%. The company had revenue of $281.11 million for the quarter. As a group, equities research analysts anticipate that Bavarian Nordic will post 0.67 EPS for the current fiscal year.

Bavarian Nordic Company Profile

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.